MEI Historical Cash Flow
| MEIP Stock | USD 2.85 0.05 1.79% |
Analysis of MEI Pharma cash flow over time is an excellent tool to project MEI Pharma future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Net Income of 16.8 M or End Period Cash Flow of 3.2 M as it is a great indicator of MEI Pharma ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining MEI Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether MEI Pharma is a good buy for the upcoming year.
MEI |
About MEI Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in MEI balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which MEI's non-liquid assets can be easily converted into cash.
MEI Pharma Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from MEI Pharma's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into MEI Pharma current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEI Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.At this time, MEI Pharma's Investments are relatively stable compared to the past year.
| 2022 | 2023 | 2024 | 2025 (projected) | Depreciation | 386K | 383K | 440.5K | 462.5K | Stock Based Compensation | 3.6M | 2.3M | 2.6M | 4.0M |
MEI Pharma cash flow statement Correlations
Click cells to compare fundamentals
MEI Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
MEI Pharma cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Sale Purchase Of Stock | 69.5M | 3.5M | (194K) | (40K) | (36K) | (34.2K) | |
| Change In Cash | (3.8M) | 7.2M | 1.2M | (13.2M) | (11.9M) | (11.3M) | |
| Change In Working Capital | 26.2M | 16.9M | (24.9M) | (84.3M) | (75.8M) | (72.1M) | |
| Begin Period Cash Flow | 12.3M | 8.5M | 15.7M | 16.9M | 19.4M | 14.3M | |
| Other Cashflows From Financing Activities | 268K | (3.3M) | (40K) | (208K) | (239.2K) | (227.2K) | |
| Other Non Cash Items | (18.1M) | (19.8M) | 1.4M | 13.4M | 12.0M | 12.6M | |
| Capital Expenditures | 708K | 479K | 35K | 7K | 8.1K | 7.6K | |
| Net Income | (50.6M) | (54.5M) | (31.8M) | 17.8M | 16.0M | 16.8M | |
| Total Cash From Financing Activities | 3.5M | 49.1M | (40K) | (11.9M) | (13.6M) | (13.0M) | |
| End Period Cash Flow | 8.5M | 15.7M | 16.9M | 3.7M | 3.3M | 3.2M | |
| Change To Liabilities | (880K) | 8.7M | 17.8M | (32.4M) | (29.1M) | (27.7M) | |
| Free Cash Flow | (32.7M) | (49.2M) | (52.5M) | (50.5M) | (45.4M) | (43.2M) | |
| Total Cash From Operating Activities | (32.0M) | (48.7M) | (52.5M) | (50.5M) | (45.4M) | (43.2M) | |
| Stock Based Compensation | 10.2M | 8.4M | 3.6M | 2.3M | 2.6M | 4.0M | |
| Depreciation | 285K | 326K | 386K | 383K | 440.5K | 462.5K | |
| Change To Inventory | 2.3M | (15.7M) | 2.5M | (10.0M) | (9.0M) | (8.5M) | |
| Total Cashflows From Investing Activities | (106.3M) | 24.7M | 6.9M | 53.7M | 61.7M | 64.8M | |
| Change To Account Receivables | 15.7M | (2.5M) | 10.0M | 85K | 97.8K | 92.9K | |
| Change To Netincome | 7.0M | (7.9M) | (11.5M) | 3.9M | 3.5M | 3.7M | |
| Investments | 25.4M | 7.4M | 53.7M | 49.1M | 56.5M | 59.3M | |
| Change To Operating Activities | (22.1M) | 22.2M | 1.6M | (2.5M) | (2.9M) | (2.8M) |
Pair Trading with MEI Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MEI Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MEI Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with MEI Stock
Moving against MEI Stock
| 0.5 | LFCR | Lifecore Biomedical | PairCorr |
| 0.44 | ALTS | ALT5 Sigma Symbol Change | PairCorr |
| 0.38 | BFRI | Biofrontera | PairCorr |
The ability to find closely correlated positions to MEI Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MEI Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MEI Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MEI Pharma to buy it.
The correlation of MEI Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MEI Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MEI Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MEI Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.